GlassScriptPhysician profile
Sara D Speaker
NPI 1700599081
$2,464.71
in general payments reported to CMS, 2019-2025
28 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $751 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.72 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.35 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $221.00 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $220.91 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $214.56 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $203.29 | 2024-2025 | |
| Dexcom, INC. | $163.66 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $163.54 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $155.26 | 2024-2025 | Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $109.83 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $101.00 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $88.92 | 2024-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $77.63 | 2025 | |
| Sumitomo Pharma America, INC. | $58.17 | 2024-2025 | Gemtesa |
| Viatris Specialty LLC | $57.67 | 2025 | Yupelri |
| Novo Nordisk INC | $44.84 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $42.46 | 2025 | Hillrom - Vest System Model 205 Acute Care |
| Exact Sciences Corporation | $37.82 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $33.91 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.49 | 2024-2025 | Jardiance |
| Tactile Systems Technology INC | $23.94 | 2025 | Flexitouch Plus, Nimbl |
| Hologic Sales and Service, LLC | $23.36 | 2025 | Thinprep 2000 Processor, Aptima |
| Eisai INC. | $22.13 | 2024 | |
| Neurocrine Biosciences, INC. | $22.03 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $20.81 | 2025 | |
| Mylan Specialty L.P. | $17.12 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $16.17 | 2024 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2024 | Xifaxan |
| Grifols USA, LLC | $13.55 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Speaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.